A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

320

Participants

Timeline

Start Date

September 8, 2025

Primary Completion Date

January 31, 2029

Study Completion Date

January 31, 2029

Conditions

Ovarian Cancer

Interventions

DRUG

Mirvetuximab Soravtansine

Intravenous (IV) infusion

DRUG

Bevacizumab

IV Infusion

DRUG

Carboplatin

IV Infusion